Drug consumption and melanocytic nevi: correlation between oral contraceptives or hormone replacement therapy and a high melanocytic nevi count. Issue 4 (July 2020)

• Record Type: Journal Article
• Authors: Colucci, Roberta; Buzzoni, Carlotta; Dragoni, Federica; Traniello Gradassi, Alessandro; Galeone, Massimiliano; Crocetti, Emanuele; Moretti, Silvia
• Is Part Of: European journal of cancer prevention. Volume 29:Issue 4(2020)
• Publication Date: 2020-07
• Subjects: drugs -- hormone replacement therapy -- melanocytic nevi -- melanoma prevention -- oral contraceptives; Cancer -- Prevention -- Periodicals; Neoplasms -- etiology -- Periodicals; Neoplasms -- prevention & control -- Periodicals; Cancer -- Prevention; Periodicals; 616.994052
• DOI: 10.1097/CEJ.0000000000000545
• Languages: English
• ISSNs: 0959-8278

Abstract

Abstract : The prolonged use of drugs such as beta-blockers, acetylsalicylic acid, omeprazole, statins, oral contraceptives and hormone replacement therapy might have some role in melanocytic nevi development and be ultimately linked to melanoma risk. Aims of the study were to evaluate a possible association between the above-mentioned drugs and features such as number and atypia of melanocytic nevi in long-term users. We retrospectively looked at pharmacological, clinical and dermoscopic records of 1321 patients that attended our unit for routine mole check between January 2013 and January 2018. Patients were divided into two groups (low or high melanocytic nevi count), and multivariate analysis was performed with regards to the presence and number of melanocytic nevi and drug assumption. A positive association between the use of oral contraceptives or hormone replacement therapy ( P = 0.012) and a high melanocytic nevi count was found through multivariate analysis, after adjusting for sex, age and multiple confounding factors, such as freckles, phototype and a reported history of sun exposure and sunburns. Further prospective studies are necessary to establish whether women using oral contraceptives or on hormone replacement therapy should undergo periodic monitoring of pigmented lesions.